|Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA||CEO & Exec. Director||N/A||N/A||1972|
|Mr. Eric Castaldi||Chief Financial Officer||N/A||N/A||1964|
|Mr. R. Keith Woods||Chief Operating Officer||N/A||N/A||1968|
|Prof. Hans de Haard||Chief Scientific Officer||N/A||N/A||1960|
|Mr. Dirk Marcel Leon Beeusaert L.L.M.||Gen. Counsel||N/A||N/A||1964|
|Mr. Arjen Lemmen M.Sc.||VP of Corp. Devel. & Strategy||N/A||N/A||1985|
|Dr. Wim Parys M.D.||Chief Medical Officer||N/A||N/A||1960|
|Joke Comijn||Director Corp. Communications & Investor Relations (EU)||N/A||N/A||N/A|
|Mr. Marc Schorpion||Global Head of HR||N/A||N/A||N/A|
|Ms. Andria Wilk||Global Head of Quality Assurance||N/A||N/A||N/A|
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
argenx SE’s ISS Governance QualityScore as of November 1, 2019 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 7.